Thoratec Corp. (THOR) Releases FY14 Earnings Guidance
Thoratec Corp. (NASDAQ:THOR) updated its FY14 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.72-1.82 for the period, compared to the Thomson Reuters consensus estimate of $1.84, AnalystRatingsNetwork reports. The company issued revenue guidance of $520-550 million, compared to the consensus revenue estimate of $535.41 million.
Several analysts have recently commented on the stock. Analysts at Raymond James cut their price target on shares of Thoratec Corp. from $46.00 to $44.00 in a research note to investors on Friday. Analysts at Zacks reiterated a neutral rating on shares of Thoratec Corp. in a research note to investors on Monday, January 6th. They now have a $38.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $45.10.
Thoratec Corp. (NASDAQ:THOR) traded up 1.69% during mid-day trading on Tuesday, hitting $34.37. The stock had a trading volume of 1,236,888 shares. Thoratec Corp. has a 52 week low of $29.91 and a 52 week high of $43.58. The stock’s 50-day moving average is $36.22 and its 200-day moving average is $37.4. The company has a market cap of $1.958 billion and a price-to-earnings ratio of 43.17.
Thoratec Corp. (NASDAQ:THOR) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by $0.03. The company had revenue of $128.20 million for the quarter, compared to the consensus estimate of $128.47 million. During the same quarter in the previous year, the company posted $0.38 earnings per share. The company’s revenue for the quarter was down .2% on a year-over-year basis. Analysts expect that Thoratec Corp. will post $1.83 earnings per share for the current fiscal year.
Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.